OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Hematology is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
	398
The latest insights into rare blood disorders: Diagnosis and treatment strategies	386
Oh node: Extranodal nodular involvement of chronic lymphocytic leukemia in the colon	234
A First‐In‐Human Phase 1 Study of a Novel BCMA × CD3 Bispecific T Cell Engager	208
Overall Survival in Male Patients With Advanced Hematological Disease (Mostly Acute Leukemia) Is Influenced by CYP1B1 C432G Polymorphism and Donor Sex in Allogeneic Stem Cell Transpl	197
Not All Tryptase Elevations Are due to Acquired Clonal Mast Cell Disorders: When Tryptase Gene Copy Number Analysis Becomes Critical	179
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations	173
The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms	151
Secondary acquisition of the Philadelphia chromosome in acute lymphoblastic leukemia	147
Association of MPL K39N and R102P heterozygous germline mutations lead to hereditary thrombocytosis	112
Introduction to American Journal of Hematology Supplement: Improving Initial Care for Acute GVHD Patients	112
Aspirin use in essential thrombocythemia: Once‐daily or twice‐daily or not at all?	110
Are veterans at increased risk of myeloproliferative neoplasms?	96
The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases	96
Teclistamab in patients with multiple myeloma and impaired renal function	93
Molecular and clinicopathologic characterization of pediatric histiocytoses	89
Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML	86
Primary Effusion Lymphoma Prognostic Score (PEL‐PS): A Validated International Prognostic Score in HIV‐Associated Primary Effusion Lymphoma	86
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative	86
Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers	81
Cytopenias revealing a case of carcinocythemia with bone marrow metastasis	79
Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients	77
Intravenous Iron Associated Hypophosphatemia: Much More Than a Laboratory Curiosity	75
The impact of sex on platelet responses to aspirin in patients with peripheral artery disease	75
Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome	73

Identifying signs and symptoms of AL amyloidosis in electronic health records using natural language processing, diagnosis codes, and manually abstracted registry data	72
A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis	71
Peripheral Blood Erythrophagocytosis in Plasmodium falciparum Malaria	71
Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR	65
Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease	65
Predictors of Relapse and Post‐Relapse Outcomes After Frontline Blinatumomab in Philadelphia Chromosome‐Negative B‐ ALL	62
Minutes Matter: An Audit of the Timeliness of Opioid Administration for Sickle Cell Disease Pain in the Emergency Department and Association With Disposition	57
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	55
TEG and ROTEM : Technology and Clinical Applications, 2026 Update	55
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers	54
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal A	53
Differential Prognosis and Transplant Strategies in CBF ‐ AML With	53
Autosomal Dominant Erythrocytosis Caused by Non‐Renal Erythropoietin ( EPO ) Due to EPO c	52
R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study	50
Clonal Hematopoiesis and Thrombosis	49
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia	48
History of Thrombosis at High Altitude Associates With Increased Erythropoietin	48
Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series	47
Table of Contents	47
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms?	46
Harnessing the prognostic potential of PHF6 mutations in chronic myelomonocytic leukemia	45